Skip to main content
Clinical Trials/ISRCTN78533119
ISRCTN78533119
Completed
Not Applicable

What is the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin?

The Newcastle Upon Tyne Hospitals NHS Foundation Trust (UK)0 sites390 target enrollmentAugust 6, 2004

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
pper limb spasticity due to stroke
Sponsor
The Newcastle Upon Tyne Hospitals NHS Foundation Trust (UK)
Enrollment
390
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 6, 2004
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Age over 18 years
  • 2\. At least 1 month since stroke
  • 3\. Upper limb (UL) spasticity (modified Ashworth scale \>2 at the elbow and/or spasticity at wrist or shoulder
  • 4\. Reduced UL function but with some general function retained (Action Research Arm Test \[ARAT] score 4\-56\)

Exclusion Criteria

  • 1\. Significant speech or cognitive impairment which will impede assessment. Participants must be able to understand and complete assessments (Abbreviated Mental Test Score \[AMTS] \>5 and Sheffield Aphasia score above age defined cut offs for receptive dysphasia).
  • 2\. Other significant upper limb impairment e.g. fracture or frozen shoulder within six months, severe arthritis, amputation
  • 3\. Evidence of contracture
  • 4\. Female patients who are pregnant or lactating or who are not willing to take adequate precautions against pregnancy for the duration of the study
  • 5\. Diagnosis likely to interfere with rehabilitation or outcome assessments e.g. registered blind, malignancy
  • 6\. Other diagnosis which may contribute to upper limb spasticity e.g. multiple sclerosis, cerebral palsy
  • 7\. Contraindications to intramuscular injection
  • 8\. Religious objections to blood products (botulinum toxin contains human albumen)
  • 9\. Contraindications to botulinum toxin which include bleeding disorders, myasthenia gravis and concurrent use of aminogycosides
  • 10\. Use of botulinum toxin to the upper limb in the previous three months

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
What is the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin?pper limb spasticity following stroke
EUCTR2004-002427-40-GBewcastle Upon Tyne Hospitals NHS Foundation Trust332
Active, not recruiting
Not Applicable
A randomised study to compare the outcomes after realignment knee surgery versus non-surgical treatment with bespoke knee physiotherapy, for patients under 60 years of age with osteoarthritis of the knee
ISRCTN99042491niversity of Edinburgh224
Active, not recruiting
Phase 4
Study of the effectiveness and safety of treatments to help patients with anaemia recover from major emergency surgery. Perioperative Iron and ESA Intervention Study (POP-I).Post-operative anaemiaHaematological Disorders
ISRCTN24330080ottingham Clinical Trials Unit2,400
Active, not recruiting
Phase 1
Clozapine in the treatment of borderline personality disorder
EUCTR2018-002471-18-GBImperial College London222
Active, not recruiting
Phase 1
IMPACT ON THE CLINICAL OUTCOMES AND COST-EFFECTIVENESS OF THE ANTIMICROBIAL THERAPEUTIC MONITORING PROGRAM IN CRITICAL PATIENTS- Respiratory infections- Urogenital infections - Abdominal infectionsMedDRA version: 20.1Level: LLTClassification code 10056570Term: Intra-abdominal infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: LLTClassification code 10038700Term: Respiratory infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: PTClassification code 10065583Term: Urogenital infection bacterialSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2019-004947-65-ESSantiago Grau Cerrato230